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ABSTRACT
Objectives: Discrepancies between abnormal cervical cytology or high-risk human papillomavirus (HR-HPV) status (cytolo- 
gy negative/HPV positive) and subsequent histological findings are a common occurrence. After using co-testing, the dis-
crepancies between the HR-HPV status and cervical cytology have become an issue. In this study, we aimed to determine 
the characteristics of women with a discrepancy between histology and cytology/HR-HPV status, in terms of diagnosis, 
review and identification. 
Material and methods: A total of 52 women, patients of the University Hospital between 2013–2015, with cytohistologi-
cal or HR-HPV status discrepancy were recruited for the study and retrospectively analyzed. The cytological samples were 
liquid-based Pap smears, classified according to the 2001 Bethesda system. The HR-HPV status was identified using the 
Hybrid Capture 2 HR-HPV DNA assay. The histological samples were obtained by cervical biopsy as well as large loop exci-
sion of the transformation zone (LLETZ). 
Results: A cytohistological discrepancy was demonstrated in patients with (-)cytology/HR-HPV(+), ASCUS, LSIL, ASC-H, HSIL, 
AGC-NOS: 17.3%, 23.07%, 26.9%, 9.5%, 17.3% and 5.7%, respectively. When the degree of atypia in cytology increases, the 
concurrency of cervical cytology with biopsy also increases. A positive HR-HPV co-test result (19/24, 79.1%) was observed 
in nearly all CIN2 ≥ (+) cases. Our study emphasizes the significance of HR-HPV testing to determine CIN2 ≥ (+) cases, even 
in the presence of a normal cytological result. 
Conclusions: In case of cytohistological or HR-HPV discrepancies, a careful review of the HR-HPV status and the degree of 
cytological atypia should be performed before further intervention.
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INTRODUCTION 
Discrepancies between abnormal cytology and histo-
logical observations are abundant, and are also associated 
with significant clinical diagnostic difficulties [1]. The dis-
crepancy rate between cytology and the subsequent histol-
ogy of cervical biopsy has been estimated at 8–28% out of 
all smear/biopsy pairs [2–5]. The presence of discrepancies 
is essentially related to diagnostic inaccuracy and sampling 
errors, as well as non-cervical pathology sampling during 
colposcopy [1, 5]. A discrepancy between cervical cytolo- 
gy and histology can cause a diagnostic conflict, which 
needs careful examination before treatment, since it has 
been shown that inaccuracies in the histological diagnoses 
affect the clinical management of the discrepancies [5]. 
Particularly, the possibility of unrecognized disease in the 
cervical canal or in the lower genital tract should be taken 
into account when the patient is diagnosed with a nega-
tive cervical biopsy or severe cytological abnormalities [5]. 
The HPV test is considered to be an important testing 
method to confirm the cytology/histology discrepancy. Nev-
ertheless, further evaluations need to be performed. In this 
study, we aimed to investigate the histopathological results 
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and the HPV status of patients with a cytology/histolo- 
gy discrepancy. 
MATERIAL AND METHODS
Between 2013 and 2015, all patients involved in the 
study were evaluated retrospectively for a suspected cytolo- 
gy/histology discrepancy. Fifty-two cases of cytology/his-
tology discrepancies were identified from the colposcopy 
database, patient chart reviews, and the results of the pa-
thology department.
All cervical smears were obtained within 2 months since 
the initial cytology and matched with the following endocer-
vical curettage samples or punch biopsies. These smears 
constituted the referral Pap smears. 
The cytology/histology discrepancy was defined as the 
variation between the cytological and histological diagnosis 
of one to two grades (major or minor) (Fig. 1), e.g. negative 
cytology and cervical intraepithelial neoplasia (CIN)1 or 
more on biopsy, or severe cytological diagnosis and nega-
tive histological diagnosis or lower histological diagnosis 
on biopsy. 
A discrepancy is considered to be ‘major’ in cases with 
high-grade cytological AGC (atypical glandular cell), ASC-H 
(atypical squamous cells cannot exclude high-grade squa-
mous intraepithelial lesion) or HSIL (high-grade squamous 
intraepithelial lesion) report and histologically benign epi-
thelium (no CIN) or CIN 1. A ‘minor’ discrepancy is identified 
as a case with low-grade cytological ASCUS (atypical squa-
mous cells of undetermined significance) or LSIL (low-grade 
squamous intraepithelial lesion) report and histological 
CIN 2–3, or cytological ASC-H, HSIL and histological CIN 2. 
Histological findings were characterized as follows: no le-
sion, CIN1, CIN2, CIN3.
All cytology samples were evaluated with liquid-based 
cytology and all histological samples were obtained during 
colposcopy-guided biopsy or large loop excisions of the 
transformation zone (TZ) (LLETZ). The study population 
were managed according to the 2012 American Society for 
Colposcopy and Cervical Pathology (ASCCP) guidelines [6]. 
Cytological findings were classified according to the 
2001 Bethesda system. During the study period, cervical 
cytology samples were processed at the Department of 
pathology, University Hospital. 
Patients with ASCUS HPV-positive were included in this 
study but those with ASCUS HPV-negative tests were ex-
cluded. Women with unsatisfactory cytology, cytology: NILM 
(negative for intraepithelial lesion or malignancy) but EC/TZ 
reported as absent/insufficient, and ASCUS with HPV(+) were 
referred to colposcopy. Subjects with ASCUS and HPV(–) 
 were referred to co-testing in 3 years, but 2 patients insisted 
on colposcopy due to anxiety, and they were included in 
the study. Women with LSIL or higher cytology, regardless 
of the HPV test result, were referred to colposcopy. All de-
tected abnormalities were biopsied. If colposcopy showed 
no lesion in the cervical quadrant, a random biopsy was 
obtained at the squamocolumnar junction in that quadrant. 
RESULTS
Mean patient age was 38.2 years. The cytological results 
were as follows: negative, ASCUS, LSIL, HSIL, AGC-NOS: 9, 12, 
14, 5, 9, 3 (total: 52) patients, respectively. The LSIL cytology 
result accounted for the major group of discrepancies and 
the discrepancy rates were (%) 26.9, 23.7, 17.3, 17.3, 9.6, 
5.7 for LSIL, ASCUS, negative cytology, HSIL, ASC-H and 
AGC-NOS, respectively. The rate of histologically benign 
epithelium (no CIN) was 6 (50%) in ASCUS, 5 (39.2%) LSIL, 
2 (40%) AC-H, 4 (44.4%) HSIL, and 1 (33.3%) AGC-NOS cytolo- 
gy, respectively (percentages are within each subgroup). 
Eighteen subjects (34.6%) were found to be ≥ ASCUS, but the 
histology was negative and inflammatory (minor discrepan-
cy). In 8 (15.3%) cases, the referral cytology was high-grade 
(ASC- H and HSIL), but the histology was low-grade (< CIN 3; 
minor discrepancy).
In the major discrepancy group, out of 22 (42.3%) cases, 
the negative referral cytology report was 5, ASCUS — 6, 
LSIL — 9, and AGC-NOS — 2 cases, but their histology sam-
ples were reported as ≥ CIN2. Out of 9 (17.3%) patients, 
the referral cytology was negative, but the histology was 
CIN 1 for 6 cases (minor discrepancy), and CIN 3 for 3 cases 
(major discrepancy). 
In summary, total major discrepancy rate was 24 (46%). 
The major discrepancy rate was higher in the HSIL group, 
77.7% (7/9), and ASC-H group 60% (3/5) as compared to 
cytology (–) 55.5% (5/9), LSIL 50% (6/12), and ASCUS 21.4% 
(3/14). As a result, there were 10 (19.2%) colposcopy-con-
firmed CIN 3 patients with missed diagnosis of high-grade 
CIN in cytology. The details of cytohistological discrepancies 
are presented in Table 1.
The HR-HPV positive rate was 79.1% (19/24) in colpo- 
scopy-confirmed CIN 2–3 groups, while this rate was 11.5% 
(3/26) in benign and CIN 1 groups. The HR-HPV positive rate Figure 1. Classification of the discrepancies
DISCREPANCIES
MINOR
1. Cytology (–)
 Biopsy: CIN 1
2. Cytology: ASCUS or LSIL
 Biopsy: CIN 2–3
3. Cytology: ASC-H or HSIL
 Biopsy: CIN 2
MAJOR
Cytology: severe diagnosis
Biopsy: (–) or lower 
histological diagnosis 
on biopsy (CIN1)
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was 100% in subjects with referral cytology (–), ASCUS, and 
LSIL, but histology CIN 3. HPV positivity was associated with 
an increase in the major discrepancy rates among cytohis-
tological discrepancies (Tab. 1). 
DISCUSSION
According to the literature, the discrepancy rate be-
tween the referral smear and the subsequent histology 
ranges between 8% and 28% [2–5]. However, there is sig-
nificant heterogeneity between the type of cervical biopsy 
and identification of the study population in the background 
population [5, 7]. Cytological errors are considered to be 
the main reasons of cytohistological discrepancies. The rea-
son of these cytological errors lies not only in cytological 
sampling errors, but also suboptimal staining quality, poor 
specimen preservation, as well as cytological interpretation 
errors [5]. 
A study of 670 smears coupled with subsequent cervical 
punch biopsy or curettage which were performed within 
2 months, found 60 cases (9%) diagnosed as cytohistolo- 
gical discrepancy. For the cases present in the sampling error 
group, errors related to cytology sampling were detected in 
40 subjects, while in 11 cases the errors were due to biopsy 
sampling [8]. The size and type of the cervical biopsy, as well 
as inadequate and inaccurate sampling of the transforma-
tion zone, have been determined as the most common 
causes of the discrepancy [7]. 
The concurrence of cervical cytology with biopsy dis-
crepancy increases with the degree of atypia in cytology. 
Another study showed that nearly 100% of cytohistological 
discrepancy cases were reported for HSIL, while this rate was 
reduced to 54% for ASCUS and 20% for AGC [9]. Heatley et 
al., showed that the correlation between punch biopsy and 
the highest grade of CIN was only 63% [10]. In our study, LSIL 
cytology results were found to be the major group of dis-
crepancy. The discrepancy rates were 26.9%, 23.7%, 17.3%, 
17.3%, 9.6%, and 5.7% for LSIL, ASCUS, negative cytology, 
HSIL, ASC-H and AGC-NOS, respectively. 
Cytohistological discrepancy among women with HSIL 
in histology is a matter of critical importance because less 
aggressive management would result in delayed diagnosis 
and treatment [11]. In our study, there were 10 (19.2%) 
colposcopy-confirmed CIN3 patients with missed diagnosis 
of high grade CIN in cytology. Importantly, accurate colpo-
scopic diagnosis depends on many factors, i.e. colposcopic 
findings, including the size of lesion, whether the colpo- 
scopy was adequate, and the experience of the colposcopist. 
Considerable variations in accurate diagnosis of colposco-
py-directed biopsy have been reported by various authors 
[12, 13]. The ability of the colposcopy-directed biopsy to ac-
curately detect the severity of cervical abnormality has been 
a major question in several studies, with the false-negative 
rate of 50%. In one study, the rate of unnoticed ≥ CIN2(+) 
disease in women with minor cytological abnormalities and 
minor colposcopic changes was 31% [11]. 
The relation between persistent infections caused by 
human papillomavirus (HPV) and the development of cervi-
cal cancer has been demonstrated [14]. The prevalence of 
HPV has been reported as 70–90% in CIN 2–3 [15]. A study 
of 252 high-grade cervical neoplasia cases showed that 98% 
of them were HR-HPV positive [14]. A recently developed 
clinical trial, Addressing the Need for Advanced HPV Diag-
nostics (ATHENA), demonstrated that HR-HPV (14 types) was 
observed in 65% of the women with CIN1, 83.3% with CIN2, 
and 92.6% with CIN3 [16], which is consistent with our study: 
HPV(+) rate — 79.1% (19/24) in CIN2 and CIN3 groups which 
were colposcopically confirmed, and 11.5% in CIN1 and no 
CIN groups.
The utility of the Papanicolaou test has been increasingly 
questioned as several meta-analyses have found the test 
inaccurate in detecting cervical cancers. It failed to diagnose 
about 50% of clinically significant pre-cancers and cancers 
which were present at the time of observation [17]. Thus, 
recently, the high-risk HPV (HR-HPV) test has become more 
reliable to detect and manage cervical squamous cancer, 
CIN2 and CIN3. 
Table 1. Referral cytology and cervical biopsy diagnosis for women referred with a cytology⁄ histology discrepancy (n =52 )
Histopathologic diagnosis/HPV (n)
Cytological diagnosis (n) No CIN HPV CIN 1 HPV CIN2 HPV CIN3 HPV Total %
Negative (9) – 4 2 3 3 17.3
ASCUS (12)* 6 –5 – 4 2 2 2 23.07
LSIL (14) 5 1 – 6 3 3 3 26.9
ASC-H (5) 2 – 1 1 2 2 – – 09.6
HSIL (9) 4 – 3 1 2 1 – – 17.3
AGC-NOS (3) 1 – – – – 2 – 5.7
Total (52) (%) 34.6   15.3   30.7   19.2    
*The ASCUS group included HPV(+) ASCUS and HPV(–) ASCUS but referred to colposcopy due to anxiety (3 cases)
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The strength of this study lies in our using cervical biopsy 
specimens to confirm the final histological diagnosis. Regard-
less, our study was not without limitations, namely lack of 
data about sexual behavior and history of previous Pap test-
ing, which might be related to cytohistological discrepancy. 
CONCLUSIONS
As was demonstrated in our study, the relation of HR-HPV 
with the major discrepancies between cytology and histo-
pathology is in accordance with the 2013 ASCCP guidelines, 
which suggested that patients with discrepancies between 
HR-HPV and cytology reports should undergo colposcopy 
and biopsy [6]. According to the recent colposcopic princi-
ples, the sensitivity in detecting high-grade CIN should be 
increased using cytology-based screening in the presence 
of high-grade referral cytology or HPV positivity [6].
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